Table 1.
Patient demographics and baseline characteristics.
| DLBCL N = 56a |
FL N = 36 |
MCL N = 12 |
Other indolent NHL N = 27 |
|
|---|---|---|---|---|
| TIRA/IDELA, N | 17 | 10 | 1 | 12 |
| Age, median (range) years | 72 (37–89) | 58 (32–70) | 70 (70–70) | 68 (41–77) |
| Female, n (%) | 5 (29) | 4 (40) | 0 | 5 (42) |
| Time since diagnosis, median (range) years | 1.5 (0.3–7.4) | 9.3 (0.3–23.0) | 3.3 (3.3–3.3) | 6.0 (0.0–9.4) |
| Ann Arbor staging, n (%)a | ||||
| I–II | 3 (18) | – | 0 | 0 |
| III or IV | 14 (82) | – | 1 (100) | 11 (92) |
| Missing | 0 | – | 0 | 1 (8) |
| Follicular lymphoma staging, n (%) | ||||
| Grade 1 | – | 0 | – | – |
| Grade 2 | – | 7 (70) | – | – |
| Grade 3a | – | 3 (30) | – | – |
| Unknown | – | 0 | – | – |
| ECOG performance status, n (%) | ||||
| 0 | 9 (53) | 3 (30) | 0 | 7 (58) |
| 1 | 8 (47) | 7 (70) | 1 (100) | 2 (25) |
| ≥2 | 0 | 0 | 0 | 2 (17) |
| Lactate dehydrogenase, U/L, median (range) | 256 (157–924) | 256 (176–970) | 237 (237–237) | 207 (72–411) |
| Prior no. of anticancer therapies, median (range) | 3.0 (1–4) | 4.0 (2–6) | 2.0 (2–2) | 2.5 (2–5) |
| Best response to last regimen, n (%) | ||||
| Complete response | 2 (12) | 0 | 0 | 2 (17) |
| Partial response | 5 (29) | 1 (10) | 1 (100) | 1 (8) |
| Stable disease | 2 (12) | 4 (40) | 0 | 1 (8) |
| Progressive disease | 6 (35) | 4 (40) | 0 | 4 (33) |
| Unknown | 2 (12) | 1 (10) | 0 | 3 (25) |
| N/A | 0 | 0 | 0 | 1 (8) |
| TIRA/ENTO, N | 39 | 26 | 11 | 15 |
| Age, median (range) years | 69 (30–89) | 67 (37–78) | 70 (61–90) | 68 (58–85) |
| Female | 12 (31) | 12 (46) | 0 | 3 (20) |
| Time since diagnosis, median (range) years | 1.7 (0.4–23.7) | 6.1 (0.3–37.7) | 4.6 (1.5–17.1) | 6.1 (1.0–19.1) |
| Ann Arbor staging, n (%)b | ||||
| I–II | 7 (18) | – | 1 (9) | 3 (20) |
| III or IV | 32 (82) | – | 9 (82) | 10 (67) |
| Missing | 0 | – | 1 (9) | 2 (13) |
| Follicular lymphoma staging, n (%) | ||||
| Grade 1 | – | 3 (12) | – | – |
| Grade 2 | – | 12 (46) | – | – |
| Grade 3a | – | 7 (27) | – | – |
| Unknown | – | 4 (15) | – | – |
| ECOG performance status, n (%) | ||||
| 0 | 19 (49) | 17 (65) | 5 (46) | 10 (67) |
| 1 | 18 (46) | 8 (31) | 6 (55) | 5 (33) |
| ≥2 | 2 (5) | 1 (4) | 0 | 0 |
| Lactate dehydrogenase, median (range) | 250 (131–956) | 222 (131–492) | 208 (146–408) | 156 (107–1107) |
| Prior no. of anticancer therapies, median (range) | 3.0 (1–7) | 3.0 (1–12) | 3.0 (2–4) | 2.0 (1–6) |
| Best response to last regimen, n (%) | ||||
| Complete response | 7 (18) | 7 (27) | 4 (36) | 3 (20) |
| Partial response | 6 (15) | 10 (39) | 2 (18) | 5 (33) |
| Stable disease | 12 (31) | 2 (8) | 3 (27) | 4 (27) |
| Progressive disease | 14 (36) | 5 (19) | 0 | 1 (7) |
| Unknown | 0 | 2 (8) | 1 (9) | 2 (13) |
| N/A | 0 | 0 | 1 (9) | 0 |
aFifty-five of the 56 DLBCL patients had non-GCB subtype, and 1 patient in the TIRA/IDELA group had GCB subtype (a protocol deviation resulting from a delayed pathology report).
bFollicular lymphoma grading was missing for 4 patients.